Northwestern University Feinberg School of Medicine, Chicago, IL
Back Injuries+12 More
Opioids - Drug
You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.
What conditions do you have?
What conditions do you have?
This study is designed to track brain functional changes in individuals with i) chronic back pain + opioid use (CBP+O) and individuals with ii) chronic back pain + opioid misuse disorder (CBP+mOUD) following a brief drug delay and re-exposure manipulation. Re-exposure could be placebo, the participant's own opioid dose, or a dopaminergic treatment (DA+NSAID). The participants will be also evaluated for changes in cognition, emotion, and motor abilities with opioid delay and re-exposure to placebo, opioid, or DA+NSAID.
Primary Treatment: Opioids · No Placebo Group · Phase 2
Chronic Back Pain with Opioid UseExperimental Group · 3 Interventions: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids · Intervention Types: Drug, Drug, Drug
Chronic Back Pain with Opioid Misuse DisorderExperimental Group · 3 Interventions: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids · Intervention Types: Drug, Drug, Drug
Drug Approval Stage
How many patients have taken this drug
Naproxen 500 Mg
Completed Phase 4
Screening: ~3 weeks
Reporting: 3 weeks
Closest Location: Northwestern University Feinberg School of Medicine · Chicago, IL
2011First Recorded Clinical Trial
1 TrialsResearching Back Injuries
144 CompletedClinical Trials
Who is running the clinical trial?
Northwestern UniversityLead Sponsor
1,421 Previous Clinical Trials
717,297 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,390 Previous Clinical Trials
24,521,477 Total Patients Enrolled
Shirley Ryan AbilityLabOTHER
167 Previous Clinical Trials
13,084 Total Patients Enrolled
Apkar V Apkarian, PhDPrincipal InvestigatorNorthwestern University Feinberg School of Medicine
3 Previous Clinical Trials
231 Total Patients Enrolled
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have had low back pain for a minimum of 6 months daily (prior to screening).
You must be able to read and understand instructions as well as questionnaires.
You must sign an informed consent document after a complete explanation of the study documenting that you understand the purpose of the study, procedures to be undertaken, possible benefits and potential risks, and are willing to participate.
You must be willing to complete daily smartphone/computer eDiary ratings.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.